Traws Pharma SEC Filings

Traws Pharma, Inc. furnished an earnings press release announcing its financial results for the quarter ended June 30, 2025, and began using a new corporate investor presentation. The earnings release is furnished as Exhibit 99.1 and the presentation as Exhibit 99.2, and the presentation will be posted on the company website.

The disclosure in Item 7.01 is incorporated by reference into Item 2.02 but is explicitly furnished, not filed, and therefore is not subject to Section 18 liabilities or automatically incorporated by reference in other filings unless specifically referenced. The Current Report and its exhibits include customary forward‑looking statements and a risk disclaimer. The 8‑K body does not contain numeric financial results; investors must review Exhibits 99.1 and 99.2 for the full figures and context.

Traws Pharma, Inc. completed an April 2024 asset acquisition of Trawsfynydd and now focuses on two lead antiviral programs, tivoxavir marboxil and ratutrelvir, while retaining oncology assets for potential partnerships. The asset acquisition included an in‑process R&D asset valued at $117.464 million.

For the three months ended June 30, 2025 the company reported $2.733 million of revenue and a net loss of $0.915 million; for the six months ended June 30, 2025 it reported $2.79 million of revenue and net income of $20.575 million, largely reflecting recognition of deferred revenue and significant changes and reclassifications of warrant liabilities. Cash and cash equivalents were $13.081 million at June 30, 2025 and the company stated it does not have sufficient cash to support operations for more than one year, noting substantial doubt about its ability to continue as a going concern. The company regained Nasdaq compliance with minimum stockholders’ equity and will be subject to a mandatory panel monitor for one year.

Traws Pharma (NASDAQ:TRAW) filed a routine Form 4 disclosing that director Clarke Trafford was granted 23,000 stock options on 06/19/2025. The options carry a $1.65 exercise price, vest 100 % after one year (06/19/2026) and expire on 06/19/2035. Following the grant, the reporting person now beneficially owns 23,000 derivative securities directly. No shares of common stock were bought or sold, and there are no indications of 10b5-1 trading plans or additional transactions in this filing.

Traws Pharma (NASDAQ:TRAW) filed a routine Form 4 reporting an insider equity grant. Director Jack E. Stover received 23,000 non-qualified stock options on 06/19/2025 at an exercise price of $1.65 per share. The options vest 100 % on the first anniversary of the grant date and expire on 06/19/2035. No open-market purchases or sales of common stock were disclosed, and the grant carries no immediate cash value to the director. Following the transaction, Stover beneficially owns 23,000 derivative securities, all held directly.

Traws Pharma (NASDAQ:TRAW) filed a routine Form 4 reporting that director Mary Teresa Shoemaker received 23,000 stock options on 06/19/2025 at an exercise price of $1.65 per share. The options vest 100% on the first anniversary of the grant date and expire on 06/19/2035. No shares were sold and no other material changes were disclosed.

Traws Pharma (TRAW) filed a routine Form 4 reporting that director Werner Cautreels received 23,000 stock options on 06/19/2025 at an exercise price of $1.65. The options vest 100% on the first anniversary of the grant date and expire on 06/19/2035. No common shares were bought or sold, and beneficial ownership remains unchanged apart from the new option grant.